Valtecne (VLT) H1 2025 earnings summary

Executive summary

• Revenues grew to €19.4M in H1 2025, with EBITDA at €4.6M and net profit at €1.9M, reflecting the impact of the Utilità S.r.l. acquisition.

• The medical segment now accounts for 75% of total revenues, up from 68.3% in H1 2024, highlighting a strategic shift and successful integration of Utilità.

• Standalone revenues for the parent company declined 3.9% YoY in H1 2025, but value of production increased by 7.7%.

• EBITDA margin improved to 23.7% in H1 2024 and remained strong at 22.6% consolidated in H1 2025.

• Net cash position in H1 2024 was €4.4M, shifting to consolidated net financial debt of €0.9M in H1 2025 due to the Utilità acquisition and dividend payout.

Financial highlights

• H1 2025 consolidated revenues: €19.4M; H1 2024 revenues: €17.08M (+0.4% YoY); Medical: €14.6M (75.1%), Industrial: €4.8M (–19.2%).

• EBITDA: €4.6M (H1 2025), €3.75M (H1 2024); EBIT: €2.91M (H1 2024); Net profit: €1.9M (H1 2025), €2.19M (H1 2024).

• Net financial debt: €0.9M (H1 2025), net cash €4.39M (H1 2024); equity: €25.7M (H1 2025), €21.9M (H1 2024).

• Adjusted EBITDA margin: 26.9% (H1 2025); standalone EBITDA margin: 21.7%.

• Capex: €1.24M in H1 2024, focused on medical and digitalization.

Outlook and guidance

• The global orthopedic market is forecast to grow 4.3% in 2025, supporting further medical expansion.

• Medical Devices backlog remains near historic highs, with double-digit growth in medical production value expected.

• Industrial segment volumes are expected to decline, but contraction should be less severe than previously anticipated.

• Full-year 2024 results expected broadly in line with 2023; FY25 group volumes may contract slightly, with a further shift toward medical.

• M&A remains a strategic priority, supported by prior strong cash position.